Opendata, web and dolomites

IMMOVA

Novel Immunotherapeutic Vaccine for the treatment of Alzheimer’s disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IMMOVA project word cloud

Explore the words cloud of the IMMOVA project. It provides you a very rough idea of what is the project "IMMOVA" about.

fraught    difficulties    made    isoforms    65    antigens    elderly    2017    added    attempt    afflicts    linked    endogenous    cc    alzinova    patient    destroys    acquire    precludes    efforts    countries    patients    efficient    families    senile    continued    unknown    therapies    27    mechanisms    irreversbly    heterogeneous    business    aggregation    neurodegeneration    alzheimer    unprecedented    plan    people    beta    strategy    administration    strategic    anti    inherently    deposition    peptide    commercialisation    trial    million    candidate    cells    acute    enter    area    primarily    delivers    thereafter    clearance    disease    prevent    vaccine    market    designed    devastating    exact    immunotherapy    ready    active    ad    humans    trade    found    cognitive    guide    stabilise    causes    oligomers    therapeutic    101    42    plaques    antigen    iia    alz    fighting    brain    context    dire    substance    bodies    passive    stop    capability    progression    unstable    clinical    treatments    fibrous    owns    launch    feat   

Project "IMMOVA" data sheet

The following table provides information about the project.

Coordinator
ALZINOVA AB 

Organization address
address: ERIK DAHLBERGSGATAN 11 A
city: GOTEBORG
postcode: 411 26
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.alzinova.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALZINOVA AB SE (GOTEBORG) coordinator 50˙000.00

Map

 Project objective

The objective of this project is to develop a business plan for the continued clinical development and commercialisation of ALZ-101 – a novel therapeutic Alzheimer´s disease (AD) vaccine candidate designed to prevent neurodegeneration in the brain.

AD is a therapeutic area in dire need of effective treatments. The disease, which primarily afflicts the elderly (65), irreversbly destroys brain cells and affects the patient’s cognitive ability. The exact mechanisms leading to AD are unknown. However, it has been found that the disease is linked to the aggregation and deposition of Aβ1-42 – one of the isoforms of fibrous Aβ peptide - into senile plaques in the brain.

In recent years, significant efforts have been made to attempt targeting the clearance of Aβ1-42 through the administration of Aβ antigens (active immunotherapy) or anti-Aβ anti-bodies (passive immunotherapy). However, the development has been fraught with difficulties. Aβ1-42 oligomers are inherently unstable and heterogeneous. This precludes the development of efficient therapies.

Alzinova owns the AβCC peptide™ technology which allows for the development of a vaccine that specifically targets the endogenous substance that causes disease – a feat made possible by the unprecedented capability to stabilise the antigen. The product will be ready to enter the clinical trial in humans by the end of 2017. In the Phase 1 project, we will develop a business plan that will guide the future clinical studies and commercialisation (to be included in the Phase 2 project). The strategy is to take the product to the Phase I/IIa level and thereafter acquire strategic partner for continued clinical studies and market launch.

Fighting AD is an EU-wide challenge as it affects 7.3 million people within the EU-27 countries. The effects of AD are devastating not only for the patients, but also for their families. ALZ-101 delivers in this context a strong EU-added value by its potential to stop the progression of AD.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMOVA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMOVA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More